NCIC CLINICAL TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING AGENDA

Hilton Montréal Bonaventure, Montréal, Québec Saturday, April 29, 2006 - 9:00 a.m. - 3:30 p.m. Room: Hampstead/Cote St. Luc

Chair: Martin Gleave

9:00 a.m.	Welcome	M. Gleave
	Approval of Fall Meeting Minutes Chairman's Report	
9:10 a.m.	NCIC CTG PHASE III TRIALS: OPEN	
	PR.8 BL.8 / EORTC 30994 BL.10	B. Donnelly L. Wood/A. Aprikian L. Klotz
9:40 a.m.	NCIC CTG PHASE III TRIALS: CLOSED	
	PR.7 / PR.7 bone sub study PR.3 PRP.1 PRP.1B – open to accrued patients BL.7 (EORTC 30987)	J. Crook/L. Klotz P. Warde N. Fleshner N. Fleshner E. Winquist/M. Moore
9:50 a.m.	NCIC CTG TRIALS APPROVED/PENDING ACTIVATION	
	PR.11 BL.11	L. Klotz L. Lacombe
10:05 a.m.	CTSU TRIALS ENDORSED BY NCIC CTG	
	*CALGB 90203 NHT Taxotere in high risk localized CaP CALGB 90202 HT with or without zoledronic acid in hormone naïve * trial in development	M. Gleave met CaP F. Saad
10:20 a.m.	BREAK	
10:40 a.m.	NCIC CTG IND TRIALS	
	IND.154: Phase I OGX-011 + Taxotere (closed) IND.161: Triapine Phase II (closed) IND.165: Randomized Phase II (OGX-011 +/- docetaxel HRPC) IND.167: (BAY 43-9006 prostate) (closed)	K. Chi J. Knox K. Chi K. Chi

continued . . .

GENITO-URINARY DISEASE SITE AGENDA

11:00 p.m. OPEN CUOG TRIALS

CUOG-R-05 Role of Delayed Treatment for Early Stage RCCa	M. Jewett
CUOG-P-05 RCT Risedronate vs Placebo for the Prevention of Androgen	
Deprivation Bone Loss in Non-Metastatic Prostate Cancer	F. Saad
CUOG B-05 BMS/CUOG second line bladder trial with vinflunine	E. Winquist
CUOG/CURC CHICS Trial	L. Klotz
CUOG P-06a Phase III Trial of docetaxel +/- high dose of Calcitriol	K. Chi

12:00 p.m. **LUNCH**

1:00 p.m. PENDING CUOG TRIALS

CUOG P-06b	Phase II Study of Patupilone (Epo906	a) as a 2nd Line
	Therapy in HRPC	K. Chi
CUOG P-06c	Phase II Study of OGX-011 + docetaxel as a 2nd Line	
	Chemotherapy in HRPC	F. Saad/E. Winquist
Taxotere Adjuvant Trial (Aventis)		D. Drachenberg/S. North
Sutent as salvage therapy in NSGCT		C. Kollmannsberger

1:40 p.m. CLOSED CUOG TRIALS

CUOG P-01b (NHT Taxotere) Taxotere as 2nd Line in HRPC Iressa® for Rising PSA post RP

2:00 p.m. TRIALS UNDER DEVELOPMENT

NCIC CTG

 NHT + Taxotere prior to XRT
 M. McKenzie

 Stampede (MRC)
 F. Saad

 RADICAL: Randomized Phase III trial of adjuvant versus selective salvage
 F. Saad

 treatment after radical prostatectomy for high-risk localized prostate cancer (MRC)
 M. McKenzie

MRC/NRCI/NCIC CTG collaborative efforts ECOG RCCa adjuvant trial

C. Catton/C. Morash N. James/C. Parker/M.Sydes M. Jewett/L. Wood

M. Gleave

F. Saad

L. Klotz

CUOG

IAS plus dutasteride in PSA failures ELAAT – early vs late Androgen Ablation Therapy Hypo fractionation RT in localized prostate cancer L. Klotz/S.L. Goldenberg A. Loblaw C. Catton

3:15 p.m. OPEN DISCUSSION – NEW BUSINESS, STRATEGIC PLANNING

3:30 p.m. **GU Executive (CLOSED)**

SPRING 2006